Who publishes this dossier

What CJC-1295 Buy is

CJC-1295 Buy is an independent editorial project that publishes summaries of the peer-reviewed research literature, the FDA regulatory record, and the anti-doping standards relating to CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier 'buy' is editorial framing — a position the publisher occupies relative to the high-volume search query around purchasing CJC-1295, not a claim about services this site offers. The dossier exists because the regulatory, clinical, and analytical record of the compound is genuinely informative public-interest material that is otherwise difficult to find behind a wall of vendor product listings.

What this site is not

This site is not a pharmacy. It does not compound, dispense, ship, broker, or take payment for any peptide, drug, or chemical preparation.

This site is not a clinic, telehealth service, or medical practice. There are no physicians on staff. There are no pharmacists on staff. There are no nurses on staff. The site does not offer consultations, prescriptions, dosing recommendations, treatment protocols, or any other clinical service.

This site is not affiliated with any manufacturer, compounding pharmacy, research-chemical vendor, telehealth platform, or wellness clinic. We do not accept advertising. We do not run affiliate links. We do not direct readers to vendors.

This site does not, anywhere in its pages, recommend the use of CJC-1295 by any person for any purpose.

Editorial standards

Every quantitative claim on every page cites a primary source — a peer-reviewed paper, a ClinicalTrials.gov record, an FDA briefing document, or a published anti-doping standard. The full citation list appears at /references and is reproduced as a plain markdown file at /references.md for crawlers and reading clients.

Where the published record contradicts non-clinical or vendor-channel claims about CJC-1295, the dossier presents the published record. Where the published record is silent — for example, on long-term human safety and efficacy outcomes — the dossier says so explicitly rather than filling the gap with inference.

The dossier does not use brand names of FDA-approved drugs in other classes. Compounds are referred to by their international nonproprietary names or recognized chemical identifiers.

Sourcing methodology

The citation set assembled for this dossier covers the published peer-reviewed literature on CJC-1295 from the 2005 Jetté identification paper through the 2024 Thomas analytical methodology paper, the ClinicalTrials.gov record for NCT00267527, the October 2024 and December 2024 FDA Pharmacy Compounding Advisory Committee briefings, and the 2025 WADA Prohibited List. Adjacent comparator literature — the Stanley 2014 tesamorelin paper on visceral fat, the Bowers 1990 GHRH-plus-GHRP synergy paper, the Steiger 1992 GHRH-sleep paper — is included where it provides essential context for findings reported on CJC-1295 itself.

Where primary sources disagree, the dossier presents the disagreement explicitly rather than selecting a single interpretation.

Disclaimer

Everything published on this site is for research and informational purposes only and is not intended as medical advice. Nothing on this site is an offer to sell, an invitation to purchase, or a recommendation to use any compound, drug, or peptide preparation. CJC-1295 is not approved by the FDA or any other major regulator for human use. The site is not affiliated with any vendor, manufacturer, pharmacy, clinic, or telehealth service. Readers seeking medical guidance should consult a licensed healthcare professional.